Drug intelligence / Profile preview

Novo-Helisen Depot (Allergopharma)

Development stage
Phase 4
Lead developer
Allergopharma
Modality
Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Subcutaneous
01

Overview

Novo-Helisen Depot (NHD) is a standardized allergen extract preparation used for subcutaneous immunotherapy (SCIT) in patients with house dust mite-induced allergic diseases. It consists of a 50/50 mixture of extracts from *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*, which are adsorbed onto aluminum hydroxide to create a depot formulation. This formulation allows for the slow release of allergens, facilitating the induction of peripheral T-cell tolerance and a shift from a Th2-mediated allergic response to a Th1/Treg-mediated immune profile. NHD is indicated for the treatment of moderate-to-severe allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma in both children and adults. The preparation is typically administered in a dose-escalation phase followed by a maintenance phase, although accelerated regimens (such as single-concentration accelerated SCIT) are also utilized to reach maintenance doses more rapidly.

Brand names
Novo-Helisen Depot
Other names
NHD double-mite allergen preparationhouse dust mite allergen extractDermatophagoides pteronyssinus and Dermatophagoides farinae allergen extractNovo-Helisen Depot mite preparation
02

Targets

Der f (Dermatophagoides farinae allergens)House dust mite allergen proteins (Dermatophagoides pteronyssinus)HDM-specific IgE (House dust mite-specific immunoglobulin E)

Beyond the preview

Go deeper on Novo-Helisen Depot (Allergopharma).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novo-Helisen Depot (Allergopharma).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call